Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363251 | 0.81 | DPP8 (0.48) | DPP8DPP9DPP4ALDH1A1 | |
| SCHEMBL7819937 | 0.71 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16039163 | 0.70 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL28046351 | 0.69 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL26139077 | 0.69 | POLB (0.32) | DPP8DPP9 | |
| SCHEMBL7819425 | 0.68 | CYP19A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7817474 | 0.68 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14690922 | 0.68 | — | — | |
| SCHEMBL25272016 | 0.67 | ALDH1A1 (0.32) | DPP8DPP9ALDH1A1SMN1; SMN2 | |
| SCHEMBL29041383 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267311-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-08-25 | — | — | US | disclosed |
| EP-3551610-B1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | UNIV TEXAS (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3551610-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10428057-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190092764-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-28 | — | — | US | disclosed |
| US-10093664-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180186781-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-05 | — | — | US | disclosed |
| WO-2018107072-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267311-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | DPP8 2529/4885DPP9 2648/4885DPP4 2666/4885 |
| US-10428057-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | CLK1, MAP3K12, CLK2 | DPP8 2529/4885DPP9 2648/4885DPP4 2666/4885 |
| US-20180186781-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | DPP8 2529/4885DPP9 2648/4885DPP4 2666/4885 |
| US-10093664-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | CLK1, MAP3K12, CLK2 | DPP8 2529/4885DPP9 2648/4885DPP4 2666/4885 |
| US-20190092764-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | DPP8 2529/4885DPP9 2648/4885DPP4 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.